Posted: November 20, 2024 at 2:48 am
BLOC fosters and promotes the professional advancement of leaders of color in the life sciences space via curated networking, mentorship and education. BLOC fosters and promotes the professional advancement of leaders of color in the life sciences space via curated networking, mentorship and education.
See the rest here:
Biopharma Leaders of Color (BLOC) Announces Board of Directors and Establishes Executive Council to Expand and Enhance Offerings
Posted: November 20, 2024 at 2:48 am
Project is part of the U.S. Department of Defense’s BioMADE initiative to support U.S. bioindustrial manufacturing innovations and workforce development Project is part of the U.S. Department of Defense’s BioMADE initiative to support U.S. bioindustrial manufacturing innovations and workforce development
Go here to read the rest:
Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel Capabilities
Posted: November 20, 2024 at 2:48 am
Company appoints Anil K. Sood, MD, as inaugural member
Continue reading here:
Kaida BioPharma Announces Formation of Scientific Advisory Board to Support Development of KAD101 for Ovarian Cancer
Posted: November 20, 2024 at 2:48 am
The waste carbon-to-ethanol facility will transform Henan Energy Group’s on-site waste gases into 50,000 tons of ethanol per year The waste carbon-to-ethanol facility will transform Henan Energy Group’s on-site waste gases into 50,000 tons of ethanol per year
Here is the original post:
Synata Bio’s Sylonto Project Awarded $4.5 Million NDRC Grant
Posted: November 20, 2024 at 2:48 am
ORION CORPORATION INVESTOR NEWS 19 NOVEMBER 2024 at 18.30 EET
Here is the original post:
Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies
Posted: November 20, 2024 at 2:48 am
IRVINE, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Helio Genomics (“Helio” or “the Company”), an AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection, today announced it will host a virtual KOL event on Monday, November 25, 2024 at 10:00 AM ET. To register, click here.
Follow this link:
Helio Genomics to Host Virtual KOL Event to Discuss Recent CLiMB Trial Data and Methylation Model Score in Patients with Hepatocellular Carcinoma...
Posted: November 20, 2024 at 2:48 am
DENVER, Nov. 19, 2024 (GLOBE NEWSWIRE) -- The 13th annual MJBizCon, the largest, most established cannabis business conference and expo in the world, opens with a more defined and inclusive expo show floor starting Wednesday, December 4, 2024 at the Las Vegas Convention Center.
Read more from the original source:
Conquer the New MJBizCon Expo Floor, One Pavilion at a Time
Posted: November 20, 2024 at 2:48 am
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from one late-breaker oral and three poster presentations at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting (TLM) 2024, being held November 15 – 19, 2024 in San Diego, CA.
Link:
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
Posted: November 20, 2024 at 2:48 am
MALVERN, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler’s 36th Annual Healthcare Conference.
Go here to read the rest:
TELA Bio to Participate in Piper Sandler’s 36th Annual Healthcare Conference
Posted: November 20, 2024 at 2:48 am
NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced an effective date for its previously-announced share consolidation. At its Annual General and Special Meeting of Shareholders, which was held on November 12, 2024, Psyence Biomed’s shareholders approved a consolidation of the Company’s common shares at a ratio of up to 1 common share for every 75 common shares held, with the final ratio to be determined by the Company’s board of directors (the “Board”). Also, as previously announced, the Board approved a 1-for-75 consolidation of its outstanding common shares.
Go here to see the original:
Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation
